ACM
BCLI

Aquatic Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Aquatic Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-53
Closed -$3K – 1092
2021
Q4 		$3K Buy
+53
New +$2.61K 0.01% 995

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return

Aquatic Capital Management's BCLI Position: Q1 2022 in Review

Aquatic Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2022, closing a stake of 53 shares — an estimated $3K sold.

Aquatic Capital Management first reported a position in BCLI in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 39 funds tracked by Wall St. Rank hold BCLI as of Q1 2022.

  • Aquatic Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2022 after selling out during the quarter.
  • Aquatic Capital Management sold 53 BRAINSTORM CELL THERAPUTC shares in Q1 2022, an estimated $3K.
  • Aquatic Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2021 and held it in 1 quarter.
  • Aquatic Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $3K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2022.

Based on Aquatic Capital Management's 13F filing for Q1 2022, filed 16 May 2022.